オプションチェーンは、Polished.com Inc Ordinary Sharesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Polished.com Inc Ordinary Sharesの市場センチメントを評価します。.

Polished.com Inc Ordinary Shares (OTC:POLC) 株価情報, オプションチェーン

Polished.com Inc Ordinary Shares

Polished.com Inc

WIIM

RPRX

Royalty Pharma shares are trading higher after the company announced it increased its quarterly dividend.

News

Guidance

IRMD

IRADIMED Reports Prelim. Q4 Revenue $19.2M-$19.4M, Prelim. FY24 Revenue $73.1M-$73.3M

On Friday, Walgreens Boots Alliance Inc&nbsp;(NASDAQ:&nbsp;WBA) reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $37.28 billion</a>, reflecting sales growth across all segments.
Adjusted operating income&nbsp;was $593 million compared to adjusted operating income of $687 million in the year-ago quarter, reflecting lower U.S. retail sales and lapping prior year sale-leaseback gains, partly offset by cost savings initiatives and growth in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42908835/walgreens-boots-alliance-reports-fiscal-2025-first-quarter-results" rel="noreferrer noopener">U.S. Healthcare segment</a>.
Adjusted EPS was&nbsp;$0.51, down from $0.66 a year ago, beating the consensus of $0.37, according to data from&nbsp;<a target="_blank" href="https://benzinga.grsm.io/register174" rel="noreferrer noopener">Benzinga Pro</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42823134/walgreens-faces-strategic-challenges-amid-analysts-cautious-optimism" rel="noreferrer noopener">Walgreens Faces Strategic Challenges, Analysts Are Cautiously Optimistic</a>
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.
Pharmacy sales increased by 10.4%, and comparable pharmacy sales increased by 12.7%, driven by higher branded drug inflation and prescription volume.
Comparable prescriptions increased by 2.3%, and prescriptions excluding immunizations increased by 3.5% compared to a year ago.
Total prescriptions filled in the quarter, including immunizations, increased 1.5% to 316.3 million.
Retail sales decreased 6.2%, and comparable retail sales decreased 4.6% compared with the year-ago quarter,&nbsp;mirroring a weaker cough cold flu season and lower sales in discretionary categories.
The U.S. Healthcare&nbsp;segment's sales were&nbsp;$2.2 billion. VillageMD sales increased 9%, CareCentrix sales increased 16%, and Shields sales rose 30%.
Guidance:&nbsp;Walgreens Boots Alliance maintains fiscal 2025 adjusted EPS&nbsp;guidance of $1.40 &#8211; $1.80 versus the consensus of $1.52.
The company <a target="_blank" href="https://investor.walgreensbootsalliance.com/static-files/b93516a3-ac11-4bf3-af48-08739983eaaf" rel="noreferrer noopener">expects</a> growth in U.S. Healthcare and International offset by pressure in U.S. Retail Pharmacy largely driven by weaker retail front end performance.
Price Action: WBA stock is up 16.3% at $10.72 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42910243/kkr-and-psp-secure-199-stake-in-american-electric-for-282b" target="_blank" rel="noreferrer noopener">American Electric Power Sells 19.9% Stake In Two Transmission Assets For $2.82B: Details</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Health Care

Movers

Trading Ideas

General

Walgreens Boots Alliance Stock Jumps On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWD&#x2122;"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Rule") after the closing bid price of the Company's common stock was $1.00 per share or greater for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule.

ONMD

OneMedNet Regains Compliance With NASDAQ Minimum Bid Price Requirements

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Friday.
Shares of PriceSmart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/PSMT/earnings">worse-than-expected first-quarter EPS results.</a>
Pricesmart posted quarterly GAAP EPS of $1.21, missing market estimates of $1.31.
PriceSmart shares fell 3.3% to $90.40 &nbsp;in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) shares tumbled 30.1% to $42.42 in pre-market trading after declining around 6% on Wednesday.</li>
<li>Vinci Partners Investments Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) shares dipped 15.5% to $8.10 in pre-market trading.</li>
<li>Urogen Pharma Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) fell 7.6% to $10.20 in pre-market trading.</li>
<li>ZIM Integrated Shipping Services Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) declined 7.4% to $19.16 in pre-market trading.</li>
<li>ORIC Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) fell 5.8% to $8.01 in pre-market trading.</li>
<li>Natwest Group PLC – ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWG#NYSE">NWG</a>) fell 5.5% to $9.30 in pre-market trading.</li>
<li>Regional Management Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RM#NYSE">RM</a>) declined 4.8% to $31.20 in pre-market trading. Regional Management will report fourth quarter results on Wednesday, Feb. 5.</li>
<li>Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) fell 2.8% to $80.70 in pre-market trading. Roku shares surged over 6% on Wednesday after the company reported surpassing 90 million streaming households in the first week of January 2025.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>

Pre-Market Outlook

Markets

ORIC

PSMT

ROKU

URGN

VINP

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and lowers the price target from $60 to $40.

Price Target

Analyst Ratings

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $40

<a href="https://www.benzinga.com/topic/chinese-stocks">US-listed Chinese stocks</a>, including Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), JD.com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), NIO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), are trading lower Friday as geopolitical tensions escalate between Washington and China over a potential artificial intelligence technology embargo on the Asian country.
Reportedly, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and other chipmakers face a <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report" rel="noreferrer noopener">potential US embargo</a> limiting AI chip exports to China. The new semiconductor sanctions could prohibit Nvidia&#8217;s AI chip shipments to nations like China.
Also Read: <a href="https://www.benzinga.com/25/01/42822512/goldman-sachs-backs-chinese-equities-as-markets-react-to-economic-slowdown-and-tariff-concerns" target="_blank" rel="noreferrer noopener">Goldman Sachs Backs Chinese Equities as Markets React to Economic Slowdown and Tariff Concerns</a>
Washington blacklisted Chinese companies, including gaming giant Tencent Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) and EV battery maker Contemporary Amperex, citing national security threats.
The Street remains jittery over China&#8217;s economic recovery. The domestic stimulus measures failed to uplift sentiments and semiconductor sanction speculations pose a double whammy.
Edith Qian of CGS International flagged a volatile first half for Chinese stocks <a href="https://www.scmp.com/business/china-business/article/3294152/hong-kong-stocks-set-worst-week-2-months-china-outlook-trade-tensions" target="_blank" rel="noreferrer noopener">to the</a> South China Morning Post (SCMP), citing the escalation of US-China bilateral tensions as the government of President-elect Donald Trump prepares to assume office on January 20.
Hong Kong&#8217;s stock market lost $118 billion in capitalization this week, the SCMP reports. China&#8217;s central bank agreed to avoid buying more government bonds to contain the yuan depreciation.
A strong US labor market has also prompted traders to resist the Federal Reserve&#8217;s rate cuts, curbing investors&#8217; appetite for stocks.
Investors can gain exposure to stocks of companies that are domiciled in China through iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) and KraneShares Trust KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>).
Read Also:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42767647/chinese-stocks-drop-as-manufacturing-growth-slows-and-geopolitical-tensions-hit" target="_blank" rel="noreferrer noopener">Chinese Stocks Drop As Manufacturing Growth Slows And Geopolitical Tensions Hit</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Tech

BABA

BIDU

KWEB

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCEHY

XPEV

Alibaba, Baidu, JD NIO, Li Auto Stocks Slide As Potential AI Chip Sanctions Add Pressure On China

The labor market ended 2024 on a strong note, adding 256,000 jobs in December, exceeding economist forecasts and showcasing once again the resilience <a href="https://www.benzinga.com/news/econ-s">of the U.S. economy. </a>
Nonfarm payrolls rose by 256,000 last month, up from the downwardly revised 212,000 in November and sharply surpassing economist expectations of 160,000 payrolls as tracked by TradingEconomics.
<h3 class="wp-block-heading">US Labor Market Defies Gravity, Unemployment Rate Falls</h3>
The December payroll figure released Friday by the Bureau of Labor Statistics surprised to the upside for the second consecutive month, signaling the U.S. labor market&#8217;s strength continues to defy gravity. The outcome marks the strongest employment growth since March 2024.
The unemployment rate fell from 4.2% to 4.1%, beating forecasts of an unchanged reading.
Average hourly earnings rose 0.3% month-over-month in December, matching expectations but slowing from November&#8217;s 0.4%. On a year-over-year basis, wages increased 3.9%, slightly below of the 4% forecast. 
<h3 class="wp-block-heading">Key Sectors Driving Employment Gains</h3>
Employment growth in December was led by gains in health care, retail trade and government, while leisure and hospitality showed minimal change.
Health care added 46,000 jobs, continuing its consistent upward trajectory, while retail trade recovered from a loss of 29,000 jobs in November, posting a gain of 43,000 jobs in December. 
Government employment was also robust, adding 33,000 positions last month. Social assistance contributed an additional 23,000 jobs, reflecting steady demand in support services.
Employment in leisure and hospitality showed little movement, with a modest increase of 43,000 jobs.
<h3 class="wp-block-heading">Market Reactions</h3>
The stronger-than-expected jobs report complicates the Federal Reserve&#8217;s path forward. 
While the labor market&#8217;s resilience signals robust economic growth for the fourth quarter, it forces policymakers to remain laser-focused on their inflation mandate, as recent price pressures have resurfaced, likely supporting a hawkish stance in the months ahead.
Yields on two-year Treasury bonds — which are highly susceptible to interest rate expectations — spiked by 11 basis points to 4.38%, reflecting fears that the Fed might push monetary easing further down the road in 2025.
The U.S. Dollar Index (DXY), which is tracked by the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rallied by 0.3% in the minutes after the release. 
Markets reacted with caution. Futures tied to the S&amp;P 500 showed a 0.6% loss in Friday&#8217;s premarket trading. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42908495/us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data">US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday&#8217;s Crucial Jobs Data</a></li>
</ul>
Photo via Shutterstock.

Macro Economic Events

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Economy Adds 256,000 Payrolls In December, Tight Labor Market Tops Forecasts: Dollar, Treasury Yields Spike

Outlook for 2025
Looking ahead to 2025, SIMPPLE is poised for continued growth and expansion. With a strengthened leadership team, diversified service offerings, and a growing international presence, we are well-positioned to capitalize on emerging opportunities across the world. Our focus will remain on enhancing operational efficiency, driving sales and innovation, and deepening partnerships within the built environment ecosystem.
In December 2024 SIMPPLE successfully regained compliance with Nasdaq listing requirements, a key milestone that reinforces our financial stability and commitment to governance excellence. We are confident in our ability to surpass our revenue targets in Q1 2025, accompanied by strong financial incentives from the Singapore government to drive robotics and automation in various industries.
With momentum leading into 2025, we remain steadfast and committed to advancing our end-to-end fit-for-purpose solutions agenda with anticipation of a great 2025 ahead of us, with more significant milestones and news to be shared. 2025 will be a year where SIMPPLE will see our strategic investments in key areas, such as Robotics and innovative sensing technologies, advanced A.I. automation, and ESG compliance and reporting, come to fruition and accelerate. We will continue to leverage our strengths in key industries like aviation, healthcare, and higher education institutions to bring best-in-class solutions to deliver long-term value to our clients.

Management

SPPL

SIMPPLE CEO Says Co Poised For 2025 Growth With Diversified Offerings, Nasdaq Compliance, And Singapore Government Support; Focus On Robotics, AI, And ESG Compliance In Key Industries Like Aviation, Healthcare, And Education; Anticipates Surpassing Revenue Targets In Q1

Biotech

TEVA

Samsung Bioepis And Teva Enter Partnership For Commercialization Of EPYSQLI In US; Samsung Bioepis Will Be Responsible For Development, Regulatory Registration, Manufacture And Supply Of The Product, While Teva Will Be Responsible For Commercialization

Kaival Brands Innovations Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>), a Delaware corporation ("Kaival" or the "Company") and the U.S. distributor of the Bidi&#xAE; Stick and certain other products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), and&nbsp;Delta Corp Holdings Limited, a company incorporated in England and Wales ("Delta") and a privately held holding company for global businesses engaged in Bulk &amp; Energy logistics, fuel supply, commodities, and asset management, jointly announced the public filing of a registration statement on Form F-4 with the U.S. Securities and Exchange Commission ("SEC") by Delta Corp Holdings Limited, a newly created holding company organized under the laws of the Cayman Islands ("Holdings" or "Pubco").
On Sept. 23, 2024, Kaival entered into a definitive business combination agreement with Delta and Pubco. This transaction will result in Kaival and Delta becoming wholly-owned subsidiaries of Pubco, which will be a new public company whose ordinary shares trade on the Nasdaq Capital Market ("Nasdaq").

KAVL

Kaival Brands Innovations Group, Inc. And Delta Corp Holdings Limited Announce Public Filing Of Registration Statement In Connection With Proposed Business Combination

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy and maintains $7 price target.

Reiteration

ABSI

HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target

Online global data marketplace accelerates BlackSky's delivery of AI-enabled analytics services to U.S. combatant commands worldwide for situational awareness and operational planning
BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) won multiple rapid procurement contracts for its high-margin, core analytics services through the U.S. Space Force's online Global Data Marketplace (GDM) supporting a variety of Tactical Surveillance, Reconnaissance and Tracking (TacSRT) missions.
"One year in operation, this novel marketplace increases speed and accessibility to BlackSky's reliable high-cadence, low-latency dynamic monitoring capabilities," said Brian O'Toole, BlackSky CEO. "BlackSky's momentum with these quick-turn contracts represents a significant structural demand signal from a key customer for operationally relevant space-based products."
The GDM has supported Space Systems Command's TacSRT pilot program and is designed to rapidly provide U.S. military combatant commands with access to insights for critical areas of interest worldwide.

Contracts

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Wins U.S. Space Force Rapid Procurement Contracts Supporting Tactical Surveillance, Reconnaissance And Tracking Missions; No Financial Terms Disclosed

VSEE

VSee Health Signs $160K Home Health And TeleNursing Contract With A Florida Health System

InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX's pipeline includes a cutting-edge, orally dosed, therapeutic candidate targeting a form of macular degeneration known as intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.

BLCO

InflammX Therapeutics Entered Option Agreement with Bausch + Lomb Granting Right To Be Acquired By BLCO

Believes Now is the Optimal Time Given the Contemplated CEO Transition
NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Barington Capital Group, L.P., which together with its affiliates collectively owns approximately 1.5% of TriMas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRS#NASDAQ">TRS</a>), announced today that it has sent a letter to Herbert K. Parker, the Chairman of the Board of Directors of TriMas, urging the Board to immediately retain a financial advisor to pursue strategic alternatives for the Company.
The full text of&nbsp;Barington's letter to Mr. Parker is available at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4336483-1&amp;h=2777267986&amp;u=https%3A%2F%2Fbarington.com%2Ftrimas&amp;a=https%3A%2F%2Fbarington.com%2Ftrimas">https://barington.com/trimas</a>&nbsp;

Barington Capital Group Calls On The Board Of Directors Of Trimas Corporation To Retain A Financial Advisor To Pursue Strategic Alternatives For The Company; Believes Now Is The Optimal Time Given The Contemplated CEO Transition

Chardan Capital analyst Daniil Gataulin initiates coverage on Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy rating and announces Price Target of $6.

Initiation

Chardan Capital Initiates Coverage On Unity Biotechnology with Buy Rating, Announces Price Target of $6

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD).
The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to assess the efficacy, safety, and tolerability of a repeat dose of fasedienol (3.2 micrograms) in adults with SAD during a public speaking challenge conducted in a clinical setting. The three dosing arms will be fasedienol followed by fasedienol (total 6.4 micrograms), fasedienol followed by placebo (total 3.2 micrograms), and placebo followed by placebo, with the second dose in each arm administered ten minutes after the initial dose. Other than the repeat dose and the additional study arm, the study is similar in design to the ongoing PALISADE Phase 3 studies for the acute treatment of adults with SAD, including an open-label extension.

VTGN

Vistagen Announces Phase 3 Program For Social Anxiety Disorder With Fasedienol; First Enrollment In U.S. Study For Efficacy, Safety, Tolerability During Public Speaking Challenge

Comments

Polished.com Inc Ordinary Shares

Polished.com Inc Ordinary Shares (POLC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル